In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating AbbVie ABBV against its key competitors in the Biotechnology industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
AbbVie Background
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| AbbVie Inc | 70.21 | 52.51 | 6.43 | 18.4% | $5.0 | $10.26 | 4.31% |
| Amgen Inc | 40.33 | 22.57 | 5.24 | 13.63% | $3.0 | $5.15 | 20.07% |
| Gilead Sciences Inc | 107.66 | 6.01 | 3.97 | 9.01% | $2.98 | $5.41 | 5.36% |
| Regeneron Pharmaceuticals Inc | 24.43 | 3.61 | 7.83 | 5.19% | $1.76 | $3.07 | 12.32% |
| Biogen Inc | 16.38 | 1.61 | 2.75 | 3.75% | $0.92 | $1.92 | 0.36% |
| United Therapeutics Corp | 15.86 | 2.64 | 6.40 | 5.04% | $0.39 | $0.64 | 19.85% |
| Genmab AS | 18.43 | 3.19 | 5.37 | 4.44% | $2.15 | $5.21 | 29.58% |
| Incyte Corp | 821.56 | 4.49 | 3.91 | 3.45% | $0.18 | $1.05 | 23.81% |
| Biomarin Pharmaceutical Inc | 40.17 | 2.35 | 4.67 | 1.98% | $0.16 | $0.58 | 4.73% |
| Neurocrine Biosciences Inc | 33.15 | 4.63 | 5.74 | 2.66% | $0.16 | $0.58 | 30.37% |
| Sarepta Therapeutics Inc | 170.26 | 11.31 | 8.29 | 0.63% | $0.03 | $0.32 | 38.93% |
| Exelixis Inc | 20.92 | 4.07 | 4.69 | 5.37% | $0.2 | $0.52 | 14.33% |
| Roivant Sciences Ltd | 2.06 | 1.60 | 62.26 | 1.67% | $0.09 | $0.05 | 154.96% |
| Average | 109.27 | 5.67 | 10.09 | 4.74% | $1.0 | $2.04 | 29.56% |
Through a meticulous analysis of AbbVie, we can observe the following trends:
-
A Price to Earnings ratio of 70.21 significantly below the industry average by 0.64x suggests undervaluation. This can make the stock appealing for those seeking growth.
-
The elevated Price to Book ratio of 52.51 relative to the industry average by 9.26x suggests company might be overvalued based on its book value.
-
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 6.43, which is 0.64x the industry average.
-
The Return on Equity (ROE) of 18.4% is 13.66% above the industry average, highlighting efficient use of equity to generate profits.
-
The company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.0 Billion, which is 5.0x above the industry average, indicating stronger profitability and robust cash flow generation.
-
The gross profit of $10.26 Billion is 5.03x above that of its industry, highlighting stronger profitability and higher earnings from its core operations.
-
The company is witnessing a substantial decline in revenue growth, with a rate of 4.31% compared to the industry average of 29.56%, which indicates a challenging sales environment.
Debt To Equity Ratio
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When evaluating AbbVie alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:
-
AbbVie holds a middle position in terms of the debt-to-equity ratio compared to its top 4 peers.
-
This indicates a balanced financial structure with a moderate level of debt and an appropriate reliance on equity financing with a debt-to-equity ratio of 10.42.
Key Takeaways
For AbbVie in the Biotechnology industry, the PE ratio is low compared to peers, indicating potential undervaluation. The high PB ratio suggests the market values AbbVie's assets highly. A low PS ratio implies sales are relatively low compared to market capitalization. AbbVie's high ROE, EBITDA, and gross profit reflect strong profitability and operational efficiency. However, the low revenue growth may indicate challenges in expanding market share compared to industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
